UNSPSC 51262608: Phentolamine hydrochloride

This classification denotes an alpha-adrenergic blocking agent with the molecular formula C17H19N3O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 86DRW83R1H, chemically known as 3-(((4,5-dihydro-1h-imidazol-2-yl)methyl)(4-methylphenyl)amino)phenol hydrochloride but more generally known as phentolamine hydrochloride, which bears US NIH Compound Identifier 66147. European Medicines Agency schedules Phentolamine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB22729.

UNSPSC 51262608 Phentolamine hydrochloride is a Commodity code that captures state and local procurement of pharmaceutical products, though recent tagged opportunities show minimal direct activity under this specific code. The sourced opportunities include naloxone procurement by Seminole County, Florida (a separate pharmaceutical acquisition aligned more closely with emergency medical supply codes) and a Texas Health and Human Services Commission RFI exploring direct-to-manufacturer prescription programs — neither of which centers on phentolamine specifically. Phentolamine is an alpha-adrenergic antagonist used clinically for hypertensive crises and pheochromocytoma management, but state and local health departments, county public health systems, and emergency medical service agencies that stock this pharmaceutical typically issue solicitations with narrower pharmaceutical-family or therapeutic-class codes rather than single-compound commodities. The issuing bodies in the recent sample span state health agencies (Texas HHS) and county health departments (Seminole County), representing the jurisdictions most likely to procure controlled pharmaceuticals through competitive bidding.

Geographic activity in the recent opportunities appears concentrated in Florida and Texas, though the sample is too limited to characterize broader state or regional patterns. The Seminole County IFB (IFB60459723LAS, posted June 30, 2026, response due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, subject to E-Verify compliance and drug-free workplace certification. The Texas HHS RFI (HHS0017013, posted April 3, 2026, response due April 3, 2026) functioned as a market-intelligence vehicle exploring direct-to-manufacturer prescription capabilities rather than a formal competitive solicitation. The code shows little recent relevant activity; vendors pursuing phentolamine sales to state and local buyers should monitor emergency medical procurement, critical-care pharmacy, and endocrinology-focused health system solicitations rather than expect dedicated phentolamine commodity codes.